Inclusion Criteria

Key inclusion criteria:

1. Male or female subjects between 18 and 75 years of age.

2. Histologically or cytologically confirmed advanced solid tumor malignancy.

3. Negative serum pregnancy test within 7 days prior to the first dose of study drug in
women of childbearing potential.

4. Agreement to use a highly effective form of contraception throughout the treatment
phase of the study in women of childbearing potential and sexually active men.

5. Body weight ≥ 50 kg for women and men and BMI within the range of 19 to 35 kg/m2
inclusive.

6. 12-lead ECG without any clinically significant abnormality as judged by the
Investigator.

7. Able to swallow oral medication.

8. Adequate organ system function.

Key exclusion criteria:

1. A positive pre-study hepatitis B surface antigen.

2. Symptomatic or acute hepatic or biliary abnormalities.

3. Clinically significant gastrointestinal abnormalities that increase the risk for
perforation.

4. Presence of uncontrolled infection.

5. Positive pre-study drug/alcohol screen.

6. Treatment with an investigational agent within the following time periods prior to
the first dose of study drug: 30 days, 5 half-lives, or twice the duration of the
biological effect of the investigational product (whichever is longest).

7. Current treatment with any cancer therapy that is causing significant
gastrointestinal side effects, including but not limited to, nausea, vomiting, and
diarrhea.

8. Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with a subject's safety, obtaining informed consent, or
compliance with the study.

9. Pregnancy or lactation.

10. Hypoalbuminemia (serum albumin <3.0 g/dL) at screening.

11. Consumption of red wine, seville oranges, grapefruit or grapefruit juice, and/or
pummelos, exotic citrus fruits, or grapefruit hybrids within 14 days prior to the
first dose of study drug.